MDMA Stock Overview
Pharmala Biotech Holdings Inc., doing business as PharmAla, engages in the manufacture and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pharmala Biotech Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.19 |
| 52 Week High | CA$0.48 |
| 52 Week Low | CA$0.085 |
| Beta | 0 |
| 1 Month Change | 11.76% |
| 3 Month Change | -32.14% |
| 1 Year Change | -50.65% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 137.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDMA | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -13.6% | 12.9% | -0.2% |
| 1Y | -50.6% | 55.8% | 7.0% |
Return vs Industry: MDMA underperformed the Canadian Pharmaceuticals industry which returned 64.2% over the past year.
Return vs Market: MDMA underperformed the Canadian Market which returned 5.3% over the past year.
Price Volatility
| MDMA volatility | |
|---|---|
| MDMA Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 15.3% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: MDMA's share price has been volatile over the past 3 months.
Volatility Over Time: MDMA's weekly volatility has decreased from 21% to 15% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Nick Kadysh | pharmala.ca |
Pharmala Biotech Holdings Inc., doing business as PharmAla, engages in the manufacture and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredient under the LaNeo brand name. The company is headquartered in Vancouver, Canada.
Pharmala Biotech Holdings Inc. Fundamentals Summary
| MDMA fundamental statistics | |
|---|---|
| Market cap | CA$16.95m |
| Earnings (TTM) | CA$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs MDMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDMA income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$0 |
| Earnings | CA$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MDMA perform over the long term?
See historical performance and comparison